or
forgot password

Phase II Study to Evaluate the Efficacy and Safety of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer


Phase 2
18 Years
N/A
Not Enrolling
Both
Non-Small Cell Lung Cancer

Thank you

Trial Information

Phase II Study to Evaluate the Efficacy and Safety of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer


Inclusion Criteria:



- Patients must have confirmed NSCLC (squamous, adeno- and large cell anaplastic
carcinoma)stage III B or Stage IV.

No prior chemotherapy regimen Patients must have adequate organ and marrow function

Exclusion Criteria:

- Untreated symptomatic brain metastasis Patients with known HIV positivity

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Response rate

Principal Investigator

Rasim Gucalp, M.D.

Investigator Role:

Study Chair

Investigator Affiliation:

Montefiore Medical Center

Authority:

United States: Food and Drug Administration

Study ID:

Velcade

NCT ID:

NCT00200382

Start Date:

May 2004

Completion Date:

May 2007

Related Keywords:

  • Non-Small Cell Lung Cancer
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms

Name

Location
Montefiore Medical Center Bronx, New York  10467-2490
Dartmouth-Hitchcock Medical Center Lebanon, New Hampshire  03756
Jacobi Medical Center Bronx, New York  10461
Albert Einstein Cancer Center Bronx, New York  10461
HealthAlliance Hospitals Fitchburg, Massachusetts  01420